Interferon-α therapy in noninfectious uveitis

Developments in Ophthalmology

Volumn 51, Issue , 2012, Pages 90-97

  Deuter, Christoph ^a   Stbiger, Nicole ^b   Zierhut, Manfred ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b Universittsmedizin Berlin ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMMUNOLOGIC FACTOR;

ARTICLE; CELLULAR IMMUNITY; DOSE RESPONSE; DRUG EFFECT; HUMAN; IMMUNOLOGY; REMISSION; UVEITIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; REMISSION INDUCTION; UVEITIS;

EID: 84860875020     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000336324     Document Type: Article

References (37)

1. Stoutenburg JP, Schrope B, Kaufmann HL: Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther 2004;8:823-835. (Pubitemid 39359866)
2. Saadeh S, Davis GL: The evolving treatment of chronic hepatitis C: where we stand a decade out. Cleve Clin J Med 2004;71:3-7.
3. Okada H, Pollack IF: Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 2004;4: 1609-1620. (Pubitemid 39371756)
4. Green AR, Vassilou GS, Curtin N, Campbell PJ: Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol J 2004;5: 126-132.
5. Theofilopoulos AN, Baccala R, Beutler B, Kono DH: Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 2005;23: 307-336. (Pubitemid 40563172)
6. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN: TLR-dependent and TLRindependent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007;13: 543-551. (Pubitemid 46828489)
7. Plskova J, Greiner K, Forrester JV: Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 2007;144: 55-61.
8. Plskova J, Greiner K, Muckersie, et al.: Interferonalpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 2006:47:3946-3950. (Pubitemid 46044311)
9. Treusch M, Vonthein R, Baur M, Günaydin I, Koch S, Stüiger N, Eckstein AK, Peter HH, Ness T, Zierhut M, Köter I: Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease. Rheumatology (Oxford) 2004;43: 1275-1282. (Pubitemid 39359304)
10. Köter I, Deuter C, Stüiger N, Zierhut M: Interferon-α (IFN-α) application versus tumor necrosis factor-α antagonism for ocular Behcet's disease: focusing more on IFN. J Rheumatol 2005; 32:1633, author reply 1634.
11. Vandenbark AA, Huan J, Agotsch M, et al.: Interferon-beta-1a treatment increases CD56 (bright) natural killer cells and CD4+CD25+Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 2009;215:125-128.
12. Yang DS, Galatowicz G, Calder VL: Upregulation of Foxp expression by recombinant interferon-alpha therapy in Behcet's disease; in ARVO, Fort Lauderdale, 2009; poster 1535.
13. Hurst EA, Mauro T: Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 2005;141:865-868. (Pubitemid 41058068)
14. Okada AA: Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 2005;13: 335-351. (Pubitemid 41702757)
15. Okada AA, Keino H, Fukai T, et al.: Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 1998;6:209-210.
16. Suzuki J, Sakai J, Okada AA: Oral administration of interferon-alpha suppresses experimental autoimmune uveoretinitis. Graefes Archiv Clin Exp Ophthalmol 2002;240:314-321. (Pubitemid 36075602)
17. Tian L, Yang P, Lei B, Shao J, Wang C, Xiang Q, Wei L, Peng Z, Kijlstra A: AAV2-mediated subretinal gene transfer of hIFN-alpha attenuates experimental autoimmune uveoretinitis in mice. PLoS One 2011;6:e19542.
18. Deuter CME, Köter I, Wallace GR, Murray PI, Stüiger N, Zierhut M: Behçet's disease: ocular effects and treatment. Prog Ret Eye Res 2008;27:111-136.
19. Mamo JG: The rate of visual loss in Behçet's disease. Arch Ophthalmol 1970;84:451-452.
20. Köter I, Güaydin I, Zierhut M, Stüiger N: The use of interferon α in Behçet disease: review of the literature. Semin Arthritis Rheum 2004;33:320-355.
21. BenEzra D, Forrester JV, Nussenblatt RB, Tabbara K, Timonen P: Uveitis Scoring System. Berlin, Springer, 1991.
22. Köter I, Zierhut M, Eckstein AK, Vonthein R, Ness T, Güaydin I, Grimbacher B, Blaschke S, Meyer-Riemann W, Peter HH, Stüiger N: Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol 2003;87:423-431. (Pubitemid 36399030)
23. Tugal-Tutkun I, Güey-Tefekli E, Urgancioglu M: Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes Arch Clin Exp Ophthalmol 2006;244:1692-1695. (Pubitemid 44830831)
24. Stüiger N, Köter I, Zierhut M: Complete regression of retinal neovascularisation after therapy with interferon alfa in Behçet's disease. Br J Ophthalmol 2000;84:1437-1438.
25. Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Kir N, Urgancioglu M: Neovascularization of the optic disc in Behçet's disease. Jpn J Ophthalmol 2006;50: 256-265. (Pubitemid 43882002)
26. Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, LeHoang P, Piette JC, Bodaghi B: Long-term efficacy and safety of lowdose interferon alpha2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol 2008;146:837-844.
27. Krause L, Altenburg A, Pleyer U, Köler AK, Zouboulis CC, Förster MH: Longterm visual prognosis of patients with ocular Adamantiades-Behçet's disease treated with interferon-α-2a. J Rheumatol 2008;35:896-903. (Pubitemid 351747134)
28. Deuter CME, Zierhut M, Möhle A, Vonthein R, Stüiger N, Köter I: Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease. Arthritis Rheum 2010;62:2796-2805.
29. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman MH, Köter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stüiger N, Yurdakul S, Yazici H, EULAR Expert Committee: EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008;67:1656-1662.
30. Deuter CM, Köter I, Güaydin I, Stüiger N, Doycheva DG, Zierhut M: Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 2009;93: 906-913.
31. Paire V, Lebreton O, Weber M: Effectiveness of interferon alpha in the treatment of uveitis macular edema refractory to corticosteroid and/or immunosuppressive treatment. J Fr Ophthalmol 2010;33: 152-162.
32. Gillies MC, Su T: Interferon-alpha 2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res 1995;49:277-288.
33. Deuter CME, Gelisken F, Stüiger N, Zierhut M, Doycheva D: Successful treatment of chronic pseudophakic macular edema (Irvine-Gass syndrome) with interferon alpha: a report of three cases. Ocul Immunol Inflamm 2011;19:216-218.
34. Sobaci G, Bayraktar Z, Bayer A: Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 2005;13:59-66. (Pubitemid 41702786)
35. Bodaghi B, Gendron G, Wechsler B, et al.: Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 2007;91:35-339.
36. Conlon KC, Urba WJ, Smith JW, et al.: Exacerbation of symptoms of autoimmune disease in patients receiving interferon-alpha therapy. Cancer 1990;65: 2237-2242. (Pubitemid 20164829)
37. Doycheva D, Deuter CME, Stüiger N et al: Interferon-alpha associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol 2009; 247:675-680.